Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 28, 2014; 20(32): 11384-11393
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11384
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11384
Table 6 Subgroup analyses comparing disease-free survival probabilities of the 160 mg/d group to their respective controls in the phase II and follow-up studies
Subgroup analyses | Phase II study | 3-yr study | ||
Week 48 | Week 156 | |||
Group A untreated | Group B 160 mg/d | Group A untreated | Group B 160 mg/d | |
Study cohort | ||||
DFS probability | 54.1% | 68.4% | 38.5% | 49.4% |
Difference | 14.3% | 10.8% | ||
95%CI | -3.4-32.0 | -7.3-29.0 | ||
Rate of improvement1 | 26.4% | 28.1% | ||
P value2 | 0.129 | 0.257 | ||
Intermediate-risk group (multiple or single tumor ≥ 2 cm) | ||||
DFS probability | 45.1% | 63.8% | 33.0% | 48.4% |
Difference | 18.7% | 15.4% | ||
95%CI | -0.8-38.2 | -3.9-34.7 | ||
Rate of improvement | 41.5% | 46.6% | ||
P value | 0.104 | 0.150 | ||
High-risk group (multiple or single tumor ≥ 2 cm and positive HBV/HCV infection)3 | ||||
DFS probability | 41.4% | 64.9% | 29.6% | 46.4% |
Difference | 23.5% | 16.8% | ||
95%CI | 2.0-45.0 | -4.4-38.1 | ||
Rate of improvement | 56.8% | 56.8% | ||
P value | 0.045 | 0.163 |
- Citation: Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SSC, Chen PJ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(32): 11384-11393
- URL: https://www.wjgnet.com/1007-9327/full/v20/i32/11384.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i32.11384